about
A highlight from the LUPUS 2014 meeting: eight great ideasI too, am America: a review of research on systemic lupus erythematosus in African-AmericansPlacental histology and neutrophil extracellular traps in lupus and pre-eclampsia pregnanciesSystemic lupus erythematosus complicated by diffuse alveolar haemorrhage: risk factors, therapy and survivalPatients with systemic lupus erythematosus and haematological malignancy at a tertiary care centre: timing, histopathology and therapyStandard medical care of patients with systemic lupus erythematosus (SLE) in large specialised centres: data from the Russian Federation, Ukraine and Republic of Kazakhstan (ESSENCE).A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis TrialAge-specific and sex-specific incidence of systemic lupus erythematosus: an estimate from cross-sectional claims data of 2.3 million people in the German statutory health insurance 2002Haematological manifestations of lupus.Lupus anticoagulant, disease activity and low complement in the first trimester are predictive of pregnancy lossSurface complement C3 fragments and cellular binding of microparticles in patients with SLEPregnancy outcomes among African-American patients with systemic lupus erythematosus compared with controlsIncreased usage of special educational services by children born to mothers with systemic lupus erythematosus and antiphospholipid antibodiesAdverse pregnancy outcomes and subsequent risk of cardiovascular disease in women with systemic lupus erythematosus.Challenges in understanding the role of pregnancy morbidity in cardiovascular risk in SLE.Role of early repeated renal biopsies in lupus nephritis.Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based studyLupus science and medicine: dialogue.Exploring lifetime occupational exposure and SLE flare: a patient-focussed pilot study.Lower vitamin D levels are associated with higher systemic lupus erythematosus activity, but not predictive of disease flare-upNecrotising fasciitis in systemic lupus erythematosus: a case report and literature review.Pathogenic autoantibodies from patients with lupus nephritis cause reduced tyrosine phosphorylation of podocyte proteins, including tubulin.Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurementsVitamin D deficiency is common and associated with increased C-reactive protein in children and young adults with lupus: an Atherosclerosis Prevention in Pediatric Lupus Erythematosus substudyBlood-based candidate biomarkers of the presence of neuropsychiatric systemic lupus erythematosus in childrenVitamin D status is a determinant of atorvastatin effect on carotid intima medial thickening progression rate in children with lupus: an Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) substudyValue of repeat biopsy in lupus nephritis flaresReduced response to Epstein-Barr virus antigens by T-cells in systemic lupus erythematosus patients.Brain MRI in patients with diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosusClinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials.Causes and outcome of hospitalisations in Tunisian patients with systemic lupus erythematosusWhich outcome measures in SLE clinical trials best reflect medical judgment?Plasma levels of galectin-3-binding protein reflect type I interferon activity and are increased in patients with systemic lupus erythematosus.Increased Th17 cells in flow cytometer-sorted CD45RO-positive memory CD4 T cells from patients with systemic lupus erythematosus.Changes in referral, treatment and outcomes in patients with systemic lupus erythematosus in Germany in the 1990s and the 2000sEvaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy.Work disability, lost productivity and associated risk factors in patients diagnosed with systemic lupus erythematosusEffect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus CohortPreliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instrumentsAssociation of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE.
P1433
Q26823803-5096A24C-88C7-4364-8E80-8E5A730DF52BQ28069750-7686FE5F-01BE-42E1-A516-076CAE0EDF47Q28603356-3A2599C0-6BB6-4649-AE55-FD15A527226DQ28607141-69309720-8B5D-4347-91E2-989D30B72968Q28651110-D8E4337F-F498-451F-A735-87207779D0EEQ30900345-DC924F4F-629E-4F2E-8CE9-8BB60B63D7F7Q31029893-D8B4EE25-B821-41A6-BABC-2A941FC68457Q31147671-7C5C5C66-7C8C-46A7-BBE9-69861EF0E74FQ33421876-43C56B77-B6E6-4970-ACF7-A0E8828B444BQ33428578-AFBCB70E-194B-4C5E-840C-1D61FC67A9BCQ33552712-20DD8D25-0174-4502-B1BF-EA57B6069CE6Q34414346-CE58921A-EE08-4237-984A-DCF19E16E39EQ34424615-4CC4377D-F1FD-4645-954F-CC1F84BE62A1Q34424622-E68B3B47-8916-4358-B9BE-CF79A10959E2Q34424626-50D625C7-576A-4BBF-B17C-3DEBB0155104Q34424633-9A42D3CB-4F62-4273-A205-8F338D275661Q34424638-9589DBF5-8771-470B-B1BA-7F98EBD23F5FQ34424643-C963B26D-5A1E-45F1-9617-E87D505CD949Q34424649-0500D662-11F1-4AB3-A059-BAA6E93DD425Q34424653-FA2398CB-1919-47FE-A238-97D6FA05D1DFQ34478773-207BC12A-2528-4675-B0C5-EBE267ED69F9Q34478786-FAB8334D-CCA4-44DD-BC6E-EC22DE18DBC9Q34478791-B7CBCDCD-EEE5-4E07-BBB8-D5F58141138BQ34478798-CFFE8CAB-1DDD-4BB7-BF2D-F183E839B4BDQ34478805-30B89D22-9E96-4908-B469-CF47FE6208BAQ34478814-FDBAD0C4-CE3C-4E31-B470-8861718799AEQ34478821-06C28E7B-B1E3-41B1-AD17-81DC01D0E64BQ34478829-15721BA1-D3B1-46BA-B992-7596B2DBC332Q34478835-862D8EE1-E90B-485B-A174-99C0A7D1EB65Q34478853-C02C7EC9-C10D-4B4A-A7B3-C7707874D5D3Q34478859-9A8D4F2A-E182-4723-B80F-590D04BC3EF3Q34478866-C4936371-D0CE-4DD7-8FFC-60F90DC2449CQ34583337-7F17FFE7-9521-47C2-AFE4-3E1F35C7408AQ34739451-53E51CB3-E907-46C0-A617-5DCE3C756EE2Q34739465-9A339FD1-33FC-4453-8DB0-15FFF1CF73CCQ35008162-41B50415-EA76-4945-9C71-60C2E0695617Q35008185-F334D84B-A19C-4FE0-B663-0B31ED6DE969Q35229284-78933FF0-70AA-40EC-AFB9-FCC88C86FB1BQ35229292-23C3FA76-51DC-46DA-B7A9-655A0624D2EFQ35233621-3B872874-ED17-45E6-A97D-714A577BD1DB
P1433
description
journal
@en
revista científica
@es
wetenschappelijk tijdschrift van BMJ Group
@nl
wissenschaftliche Fachzeitschrift
@de
name
Lupus science & medicine
@ast
Lupus science & medicine
@en
Lupus science & medicine
@es
Lupus science & medicine
@nl
type
label
Lupus science & medicine
@ast
Lupus science & medicine
@en
Lupus science & medicine
@es
Lupus science & medicine
@nl
altLabel
Lupus Sci Med
@en
Lupus Science and Medicine
@en
prefLabel
Lupus science & medicine
@ast
Lupus science & medicine
@en
Lupus science & medicine
@es
Lupus science & medicine
@nl
P31
P3181
P1055
P1156
21100428281
P123
P1476
Lupus science & medicine
@en